# Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors

> **NCT04611711** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 60 (estimated)

## Conditions studied

- Patients With Digestive System Tumors Resistant to PD-1 Inhibitors

## Interventions

- **DRUG:** decitabine＋ TQB2450 injection
- **DRUG:** decitabine＋ TQB2450 injection＋Anlotinib

## Key facts

- **NCT ID:** NCT04611711
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04611711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04611711, "Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04611711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*